Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Pinsky PF, Black A, Daugherty SE, Hoover R, Parnes H, Smith ZL, Eggener S, Andriole GL, Berndt SI.

Cancer. 2019 May 8. doi: 10.1002/cncr.32176. [Epub ahead of print]

PMID:
31067347
2.

Overall mortality in men and women in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Pinsky PF, Miller EA, Zhu CS, Prorok PC.

J Med Screen. 2019 Apr 3:969141319839097. doi: 10.1177/0969141319839097. [Epub ahead of print]

PMID:
30943843
3.

Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.

Pierre-Victor D, Pinsky PF.

JAMA Intern Med. 2019 Feb 1;179(2):196-203. doi: 10.1001/jamainternmed.2018.5982.

PMID:
30592477
4.

Correction to: The relationship between diabetes, prostate-specific antigen screening tests, and prostate cancer.

Miller EA, Pinsky PF, Pierre-Victor D.

Cancer Causes Control. 2019 Feb;30(2):215-216. doi: 10.1007/s10552-018-1097-x.

PMID:
30506128
5.

Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial.

Miller EA, Pinsky PF, Schoen RE, Prorok PC, Church TR.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):101-110. doi: 10.1016/S2468-1253(18)30358-3. Epub 2018 Nov 29.

PMID:
30502933
6.

Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.

Pinsky PF, Miller E, Prorok P, Grubb R, Crawford ED, Andriole G.

BJU Int. 2019 May;123(5):854-860. doi: 10.1111/bju.14580. Epub 2018 Nov 2.

PMID:
30288918
7.

Power of a Trial Investigating a Low-Intensity PSA-Based Screening Intervention.

Pinsky PF.

JAMA. 2018 Aug 14;320(6):600. doi: 10.1001/jama.2018.7327. No abstract available.

PMID:
30120468
8.

The relationship between diabetes, prostate-specific antigen screening tests, and prostate cancer.

Miller EA, Pinsky PF, Pierre-Victor D.

Cancer Causes Control. 2018 Oct;29(10):907-914. doi: 10.1007/s10552-018-1067-3. Epub 2018 Aug 9. Erratum in: Cancer Causes Control. 2019 Feb;30(2):215-216.

PMID:
30094676
9.

Lung cancer screening with low-dose CT: a world-wide view.

Pinsky PF.

Transl Lung Cancer Res. 2018 Jun;7(3):234-242. doi: 10.21037/tlcr.2018.05.12. Review.

10.

Number of Adenomas Removed and Colorectal Cancers Prevented in Randomized Trials of Flexible Sigmoidoscopy Screening.

Pinsky PF, Loberg M, Senore C, Wooldrage K, Atkin W, Bretthauer M, Cross AJ, Hoff G, Holme O, Kalager M, Segnan N, Schoen RE.

Gastroenterology. 2018 Oct;155(4):1059-1068.e2. doi: 10.1053/j.gastro.2018.06.040. Epub 2018 Jun 20.

PMID:
29935150
11.

Association of Colonoscopy Adenoma Findings With Long-term Colorectal Cancer Incidence.

Click B, Pinsky PF, Hickey T, Doroudi M, Schoen RE.

JAMA. 2018 May 15;319(19):2021-2031. doi: 10.1001/jama.2018.5809.

PMID:
29800214
12.

Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.

Miller EA, Pinsky PF, Black A, Andriole GL, Pierre-Victor D.

Prostate. 2018 Aug;78(11):830-838. doi: 10.1002/pros.23540. Epub 2018 Apr 17.

PMID:
29667217
13.

Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.

Pinsky PF, Miller E, Heckman-Stoddard B, Minasian L.

Am J Obstet Gynecol. 2018 Jun;218(6):606.e1-606.e9. doi: 10.1016/j.ajog.2018.03.031. Epub 2018 Apr 7.

14.

Comment on "Systematic review and meta-analysis by Dube et al."

Pinsky PF.

Am J Gastroenterol. 2018 May;113(5):780-781. doi: 10.1038/s41395-018-0003-1. Epub 2018 Feb 16. No abstract available.

PMID:
29453379
15.

Does the evidence support the implementation of lung cancer screening with low-dose computed tomography?

Pinsky PF.

Expert Rev Respir Med. 2018 Apr;12(4):257-260. doi: 10.1080/17476348.2018.1428564. Epub 2018 Jan 19. No abstract available.

PMID:
29338501
16.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R.

Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.

17.

Early detection versus primary prevention in the PLCO flexible sigmoidoscopy screening trial: Which has the greatest impact on mortality?

Doroudi M, Schoen RE, Pinsky PF.

Cancer. 2017 Dec 15;123(24):4815-4822. doi: 10.1002/cncr.31034. Epub 2017 Oct 4.

18.

False-positive screens and lung cancer risk in the National Lung Screening Trial: Implications for shared decision-making.

Pinsky PF, Bellinger CR, Miller DP Jr.

J Med Screen. 2018 Jun;25(2):110-112. doi: 10.1177/0969141317727771. Epub 2017 Sep 20.

PMID:
28929865
19.

Lung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial.

Pinsky PF, Gierada DS, Nath PH, Munden R.

AJR Am J Roentgenol. 2017 Nov;209(5):1009-1014. doi: 10.2214/AJR.17.18252. Epub 2017 Sep 12.

PMID:
28898131
20.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R.

Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.

21.

Prostate Cancer Screening.

Pinsky PF, Prorok PC, Kramer BJ.

N Engl J Med. 2017 Jun 15;376(24):2402. doi: 10.1056/NEJMc1705480. No abstract available.

PMID:
28614680
22.

Data sharing in clinical trials: An experience with two large cancer screening trials.

Zhu CS, Pinsky PF, Moler JE, Kukwa A, Mabie J, Rathmell JM, Riley T, Prorok PC, Berg CD.

PLoS Med. 2017 May 23;14(5):e1002304. doi: 10.1371/journal.pmed.1002304. eCollection 2017 May.

23.

Incidental renal tumours on low-dose CT lung cancer screening exams.

Pinsky PF, Dunn B, Gierada D, Nath PH, Munden R, Berland L, Kramer BS.

J Med Screen. 2017 Jun;24(2):104-109. doi: 10.1177/0969141316657115. Epub 2016 Oct 9.

PMID:
28482765
24.

Commentary on "Screening for lung cancer" by Sateia et al.

Pinsky PF.

Semin Oncol. 2017 Feb;44(1):83-84. doi: 10.1053/j.seminoncol.2017.02.005. Epub 2017 Feb 8. No abstract available.

PMID:
28395769
25.

Prostate Cancer Screening - A Perspective on the Current State of the Evidence.

Pinsky PF, Prorok PC, Kramer BS.

N Engl J Med. 2017 Mar 30;376(13):1285-1289. doi: 10.1056/NEJMsb1616281. No abstract available.

PMID:
28355509
26.

Flexible sigmoidoscopy screening: is once enough?

Pinsky PF.

Lancet. 2017 Apr 1;389(10076):1275-1277. doi: 10.1016/S0140-6736(17)30542-1. Epub 2017 Feb 22. No abstract available.

27.

Interval lung cancer after a negative CT screening examination: CT findings and outcomes in National Lung Screening Trial participants.

Gierada DS, Pinsky PF, Duan F, Garg K, Hart EM, Kazerooni EA, Nath H, Watts JR Jr, Aberle DR.

Eur Radiol. 2017 Aug;27(8):3249-3256. doi: 10.1007/s00330-016-4705-8. Epub 2017 Jan 3.

PMID:
28050695
28.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL.

Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.

29.

The bimanual ovarian palpation examination in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications.

Doroudi M, Kramer BS, Pinsky PF.

J Med Screen. 2017 Dec;24(4):220-222. doi: 10.1177/0969141316680381. Epub 2016 Nov 30.

PMID:
27903809
30.

Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps.

Marcus PM, Pashayan N, Church TR, Doria-Rose VP, Gould MK, Hubbard RA, Marrone M, Miglioretti DL, Pharoah PD, Pinsky PF, Rendle KA, Robbins HA, Roberts MC, Rolland B, Schiffman M, Tiro JA, Zauber AG, Winn DM, Khoury MJ.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1449-1455. Epub 2016 Aug 9.

31.

Colorectal Cancer Screening.

Pinsky PF, Doroudi M.

JAMA. 2016 Oct 25;316(16):1715. doi: 10.1001/jama.2016.13849. No abstract available.

PMID:
27784086
32.

Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, Gohagan J, Berg CD, Prorok PC.

Gynecol Oncol. 2016 Nov;143(2):270-275. doi: 10.1016/j.ygyno.2016.08.334. Epub 2016 Sep 9.

33.

Active follow-up versus passive linkage with cancer registries for case ascertainment in a cohort.

Pinsky PF, Yu K, Black A, Huang WY, Prorok PC.

Cancer Epidemiol. 2016 Dec;45:26-31. doi: 10.1016/j.canep.2016.09.003. Epub 2016 Sep 26.

34.

The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource.

Zhu CS, Huang WY, Pinsky PF, Berg CD, Sherman M, Yu KJ, Carrick DM, Black A, Hoover R, Lenz P, Williams C, Hawkins L, Chaloux M, Yurgalevitch S, Mathew S, Miller A, Olivo V, Khan A, Pretzel SM, Multerer D, Beckmann P, Broski KG, Freedman ND.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1635-1642. Epub 2016 Sep 15.

35.

Definition of Specificity in a Screening Trial.

Pinsky PF.

J Clin Oncol. 2016 Jan 10;34(2):198. doi: 10.1200/JCO.2015.62.9253. Epub 2015 Nov 16. No abstract available.

PMID:
26573070
36.

Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.

Pinsky PF, Kramer BS.

J Natl Cancer Inst. 2015 Oct 19;107(11). pii: djv226. doi: 10.1093/jnci/djv226. Print 2015 Nov.

37.

Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial.

Gohagan JK, Broski K, Gren LH, Fouad MN, Higgins D, Lappe K, Ogden S, Shambaugh V, Pinsky PF, O'Brien B, Yurgalevich S, Riley T, Wright P, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):187-93. Review.

PMID:
26435288
38.

Principles of Cancer Screening.

Pinsky PF.

Surg Clin North Am. 2015 Oct;95(5):953-66. doi: 10.1016/j.suc.2015.05.009. Epub 2015 Jun 20. Review.

39.

Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer.

Schoen RE, Razzak A, Yu KJ, Berndt SI, Firl K, Riley TL, Pinsky PF.

Gastroenterology. 2015 Nov;149(6):1438-1445.e1. doi: 10.1053/j.gastro.2015.07.055. Epub 2015 Aug 5.

40.

Lung cancer risk by years since quitting in 30+ pack year smokers.

Pinsky PF, Zhu CS, Kramer BS.

J Med Screen. 2015 Sep;22(3):151-7. doi: 10.1177/0969141315579119. Epub 2015 Apr 29.

PMID:
25926339
41.

Occurrence of Distal Colorectal Neoplasia Among Whites and Blacks Following Negative Flexible Sigmoidoscopy: An Analysis of PLCO Trial.

Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Hickey T, Riley T, Church TR, Weissfeld J, Schoen RE, Marcus PM, Prorok PC.

J Gen Intern Med. 2015 Oct;30(10):1447-53. doi: 10.1007/s11606-015-3297-3. Epub 2015 Apr 3.

42.

Colorectal cancer incidence by age among patients undergoing surveillance colonoscopy.

Pinsky PF, Schoen RE.

JAMA Intern Med. 2015 May;175(5):858-60. doi: 10.1001/jamainternmed.2015.0344. No abstract available.

PMID:
25822077
43.

Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.

Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, Kazerooni E.

Ann Intern Med. 2015 Apr 7;162(7):485-91. doi: 10.7326/M14-2086.

44.

Cost-effectiveness of CT screening in the National Lung Screening Trial.

Pinsky PF.

N Engl J Med. 2015 Jan 22;372(4):387. doi: 10.1056/NEJMc1414726. No abstract available.

PMID:
25607438
45.

Re: prostate cancer mortality in areas with high and low prostate cancer incidence.

Pinsky PF.

J Natl Cancer Inst. 2014 Sep 30;106(10). pii: dju292. doi: 10.1093/jnci/dju292. Print 2014 Oct. No abstract available.

46.

National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population.

Pinsky PF, Gierada DS, Hocking W, Patz EF Jr, Kramer BS.

Ann Intern Med. 2014 Nov 4;161(9):627-33. doi: 10.7326/M14-1484.

47.

Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer.

Black A, Pinsky PF, Grubb RL 3rd, Falk RT, Hsing AW, Chu L, Meyer T, Veenstra TD, Xu X, Yu K, Ziegler RG, Brinton LA, Hoover RN, Cook MB.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2374-82. doi: 10.1158/1055-9965.EPI-14-0700. Epub 2014 Sep 1.

48.

Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling.

McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, Kong CY, Choi SE, Munshi VN, Han SS, van Rosmalen J, Pinsky PF, Moolgavkar S, de Koning HJ, Feuer EJ.

PLoS One. 2014 Jun 30;9(6):e99978. doi: 10.1371/journal.pone.0099978. eCollection 2014.

49.

Can symptomatic cancer be distinguished from screen detected cancer?

Schoen RE, Pinsky PF.

Gastroenterology. 2014 Aug;147(2):545-6. doi: 10.1053/j.gastro.2014.05.044. Epub 2014 Jun 25. No abstract available.

PMID:
24973674
50.

Short- and long-term lung cancer risk associated with noncalcified nodules observed on low-dose CT.

Pinsky PF, Nath PH, Gierada DS, Sonavane S, Szabo E.

Cancer Prev Res (Phila). 2014 Dec;7(12):1179-85. doi: 10.1158/1940-6207.CAPR-13-0438. Epub 2014 Apr 22.

Supplemental Content

Loading ...
Support Center